A trial emulation study of veterans with COVID-19 found that the use of the antiviral nirmatrelvir–ritonavir (Paxlovid) was not effective for reducing the risk for many post-COVID-19 conditions.
The study found individuals with long COVID were more likely to experience pulmonary embolism, asthma, and chronic obstructive pulmonary disease.
There is a slightly elevated risk of intracranial thrombosis events following vaccination with the AstraZeneca ChAdOx1-S COVID vaccine, according to two new studies published in Plos Medicine
The FDA approved Pradaxa oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism directly after they have been treated with a blood thinner given by injection for at least five days.
Read More
Researchers at Rutgers Robert Wood Johnson Medical School are reporting the first instance of COVID-19 triggering a rare recurrence of potentially serious blood clots in people’s arms.
Read More
Only a small percentage of hospitalized patients with acute pulmonary embolism are discharged home from the emergency department, according to new research in the Academic Emergency Medicine journal.
Read MoreCOPD patients who were hospitalized for respiratory symptoms had a prevalence of pulmonary embolism of 5.9%.
Read More
A small study of five patients with COVID-19 found that treatment with tPA — a thrombolyic agent used to dissolve blood clots — resulted in rapid improvement in alveolar ventilation, oxygenation, and/or shock.
Read More
New research suggests that there may be a reduced incidence of deep vein thrombosis (DVT) in patients who are at high risk of pulmonary embolism (PE).
Read More
The first two generics of Eliquis (apixaban) have been approved for cardiopulmonary conditions, including deep vein thrombosis and pulmonary embolism.
Read More
Smokers with pulmonary emboli are more likely to be readmitted for PE than nonsmokers, according to research at Chest 2019 in New Orleans.
Read More
Despite low incidence, pulmonary embolism is one of the leading causes of maternal mortality, with several challenges to proper diagnosis.
Read MoreMultiorgan, point-of-care ultrasound at the patient’s bedside increased the accuracy of diagnosing patients with suspected pulmonary embolism, according to a study published in CHEST.
Read MoreThe FDA has cleared the EkoSonic Endovascular System for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism (PE).
Read More
The FDA has approved Pradaxa (dabigatran etexilate mesylate) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in certain patients, according to Boehringer Ingelheim Pharmaceuticals.
Read More